

Anti-Human IgG F(ab')₂ (Fluorescein Conjugated) Secondary Antibody

Goat Polyclonal, Fluorescein (FITC)

Catalog # ASR1595

Product Information

Description	Anti-HUMAN IgG F(ab') ₂ (GOAT) Antibody Fluorescein Conjugated
Host	Goat
Conjugate	Fluorescein (FITC)
FP Value	3.0 moles Fluorescein (FITC) per mole of IgG
Target Species	Human
Clonality	Polyclonal
Physical State	Lyophilized
Host Isotype	IgG
Target Isotype	IgG F(ab') ₂
Buffer	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Immunogen	Human IgG F(ab') ₂ fragment
Reconstitution Volume	1.0 mL
Reconstitution Buffer	Restore with deionized water (or equivalent)
Stabilizer	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Preservative	0.01% (w/v) Sodium Azide

Additional Information

Shipping Condition	Ambient
Purity	This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Fluorescein, anti-Goat Serum, Human IgG, Human IgG F(ab') ₂ and Human Serum. No reaction was observed against Human IgG F(c).
Storage Condition	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Precautions Note	This product is for research use only and is not intended for therapeutic or diagnostic applications.

Background

This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor

imaging, utilizing various commercial platforms.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.